Cybin Inc.
Small Pharma has received approval for an interaction study between the company’s lead N, N-dimethyltryptamine (DMT) candidate – SPL026 – and serotonin reuptake inhibitors (SSRIs).
Clinilabs Drug Development Corporation has begun enrolment in a Phase 1/2a clinical trial of Cybin’s CYB003 for the treatment of major depressive disorder (MDD).
Cybin has confirmed that it has received a “may proceed letter” and Investigational New Drug Application (IND) clearance from the U.S.
A new study has revealed how ketamine works, which scientists say paves the way toward the development of safe, effective treatments for depression.
Cybin has confirmed it has received approval for its Phase 1/2a trial evaluating its proprietary deuterated psilocybin analogue for the treatment of Major Depressive Disorder (MDD).
The first patient has been dosed in HMNC and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study.
Results from two-combined studies have revealed that psilocybin-assisted therapy increased brain activity in people with depression for up to three weeks following use.
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
Cybin Inc.
